Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Pediatric-onset multiple sclerosis (POMS) is a rare neuroinflammatory and
neurodegenerative disease that has a significant impact on long-term physical and cognitive …

Multiple sclerosis (MS) primarily affects adult females. However, in the last decades, rising
incidence and prevalence have been observed for demographic extremes, such as pediatric …

Abstract Purpose of Review Multiple sclerosis is a chronic inflammatory disease of the
central nervous system. When seen in children and adolescents, crucial stages of brain …

The current diagnostic criteria for pediatric onset multiple sclerosis (POMS) are summarized,
as well as the evidence for performance of the most recent iteration of McDonald criteria in …

Background High-efficacy disease-modifying therapies have been proven to slow disability
accrual in adults with relapsing–remitting multiple sclerosis. However, their impact on …

Background: The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for
teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS). Objective …

Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central
nervous system. Relapsing–remitting MS (RRMS), the most common form of the disease, is …

Introduction Different disease-modifying therapies (DMTs) have been developed to slow
down the progression of pediatric multiple sclerosis (MS). Teriflunomide is one such DMT …

Objectives Long-term immunomodulatory therapy of pediatric onset-multiple sclerosis
(POMS) is based mainly on published case series and internationally agreed guidelines …